†rsrapport Nycomed - Takeda Pharmaceuticals International GmbH

BUSINESS DESCRIPTIONMAIN PRODUCTS®Xefo ® is a non-steroidal anti-inflammatory drug (NSAID) with potent analgesic(pain relieving) properties. These are two different qualities that make Xefo ®appropriate for both rheuma and pain indications. Clinical studies have shownthat Xefo ® is as efficacious as morphine and other opioids in standard dosesfor post-operative pain. However, Xefo ® has a far better side effect profile thanopioids, which is a major advantage in, for example, ambulatory surgery.Xefo ® is currently marketed in Denmark, Sweden, Germany, UK, Austria,Greece, Portugal, Spain, Bulgaria, Russia, the three Baltic countries and SouthAfrica. Xefo ® will soon be marketed in Italy, Japan and possibly other markets.In addition, Nycomed has obtained a marketing authorisation for the product inmany other countries, and several companies report an interest in in-licensingXefo ® .Nycomed has followed Xefo ® from the discovery of the compound in Austria inthe 1970s and conducted many pre-clinical and clinical studies before Xefo ®was approved by the health authorities.Sales 1999Sales 2000DKK 38 millionDKK 53 million(+41.3% from 1999)–27–